Aktieägarna i Karolinska Development AB (publ) kallas till extra bolagsstämma
October 15, 2024 06:10 ET
|
Karolinska Development AB (publ)
Aktieägarna i Karolinska Development AB (publ), org.nr 556707-5048, (“Karolinska Development” eller “Bolaget”), kallas till extra bolagsstämma onsdagen den 13 november 2024 kl. 11.00 hos Cirio...
Notice of Extraordinary General Meeting in Karolinska Development AB (publ)
October 15, 2024 06:10 ET
|
Karolinska Development AB (publ)
The shareholders of Karolinska Development AB (publ), reg. no. 556707-5048, (“Karolinska Development” or the “Company”) are invited to the Extraordinary General Meeting (“EGM”), on Wednesday, November...
Karolinska Development avyttrar hela innehavet i det danska dermatologibolaget Henlez
September 23, 2024 10:26 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SVERIGE 23 september 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar att bolaget säljer samtliga aktier i portföljbolaget Henlez ApS. Efter avyttringen består Karolinska...
Karolinska Development divests its holding in the Danish dermatology company Henlez
September 23, 2024 10:26 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SWEDEN, September 23 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces the divestment of all its shares in the portfolio company Henlez ApS. Following the transaction,...
Karolinska Developments portföljbolag AnaCardio rapporterar framsteg i två kliniska studier av läkemedelskandidaten AC01
September 17, 2024 02:35 ET
|
Karolinska Development AB (publ)
STOCKHOLM, 17 september 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget AnaCardio har slutfört den kliniska studien AC01-FE som genomförts i USA parallellt...
Karolinska Development’s portfolio company AnaCardio reports progress in two clinical trials with its drug candidate AC01
September 17, 2024 02:35 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SWEDEN September 17, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company AnaCardio has completed the AC01-FE study in the US and also...
Karolinska Developments portföljbolag BOOST Pharma presenterar positiva top line-resultat från en fas 1/2-studie med över 75% minskning av frakturfrekvensen hos barn med sällsynt bensjukdom
September 17, 2024 02:05 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SVERIGE, 17 september 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget BOOST Pharma presenterat positiva top line-resultat från en klinisk fas...
Karolinska Developments portfolio company BOOST Pharma announces positive top-line results from a Phase 1/2 study with over 75% reduction of fracture rates in children with rare bone disease
September 17, 2024 02:05 ET
|
Karolinska Development AB (publ)
STOCKHOLM, SWEDEN, September 17 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company BOOST Pharma has presented positive top-line results from a clinical...
Karolinska Developments portföljbolag Biosergen meddelar framgångsrik behandling av första patienten i klinisk studie med BSG005
August 30, 2024 09:03 ET
|
Karolinska Development AB (publ)
STOCKHOLM 30 augusti 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) meddelar idag att portföljbolaget Biosergen har behandlat den första patienten med läkemedelskandidaten BSG005 i en...
Karolinska Development’s portfolio company Biosergen announces successful treatment of first patient in a clinical trial of BSG005
August 30, 2024 09:03 ET
|
Karolinska Development AB (publ)
STOCKHOLM, Sweden, August 30 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Biosergen has treated the first patient with the drug candidate BSG005...